Farmas USA

ya somos dos y encima es que me va la marcha, esa es la duda que el gráfico es bajista y fallado en la rotura cualquiera le mete,

http://www.thelifesciencesreport.com/pub/na/16334

OMER THLD CERS PPHM NVAX

thld
me salto stop en 3.11 no estoy dentro

Zgnx

Si contáis al cocinero ya sois 3. $heff acaba de entrar en 1'24

no entré, hoy no mañanaaaaaaaaaaaaaaaaaa

http://www.smarteranalyst.com/2014/11/13/h-c-wainwright-reiterates-buy-on-threshold-pharmaceuticals-sees-264-upside-for-stock/

In a research note released yesterday, H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Threshold Pharmaceuticals (NASDAQ:THLD) with a $12 price target which represents a 264% upside from where the stock is currently trading.

Fein wrote, “Although the sarcoma program is scheduled to take a first shot at clinical and commercial success (data in 1Q16), it is the close-following pancreatic cancer program (data later in 2016) that unlocks greater value ($250M vs. $1.5B), while also in our view having even higher probability of success. Importantly, while THLD and its partner Merck continue to invest on the wide potential of TH-302 beyond STS and PC, we believe that the current trading levels of THLD shares offer a discount even to a base scenario of success consisting of: (1) launch of TH-302 in the STS and PC indications only; (2) conservative probability of success (60% for STS, 75% for PC); and (3) commercialization of TH-302 by Merck KGaA and revenues to THLD based on a royalty model only. Success in STS and/or PC, expansion into additional indications (such as NSCLC, GBM, or MM), and election by THLD to exercise its option to co-commercialize TH-302 with Merck KGaA in the US, would provide significant upside to our estimates and price target.“

THLD

El volumen es muy alto.... sospechoso...
ZGNX

venta de 400.000 en un bloque, es venta en IB confirmarlo el que pueda.